The vasoactive peptide endothelin-1 (ET-1) has been implicated in promoting the progression of prostate and other cancers though its precise mechanism(s)-of-action remain unclear. To better define the role of ET-1 in prostate cancer progression, we generated prostate cancer cell lines (PC-3 and 22Rv1) that express elevated levels of ET-1. As anticipated, increased ET-1 lead to modest autocrine growth stimulation of PC-3 cells in monolayer culture and increased colony formation in soft agar by both cell lines. Unexpectedly, however, metastatic colonization of 22Rv1 cells expressing elevated levels of ET-1 was reduced, as was the size of subcutaneous tumors produced by both 22Rv1-and PC-3 cells. Based on these data, we hypothesized that high levels of ET-1 may negatively impact the tumor microenvironment. We found that increased ET-1 expression did not consistently inhibit angiogenesis, indicating that this was not the cause of poor tumor growth. As an alternative explanation, we examined whether elevated ET-1 results in local vasoconstriction and thus reduces the blood supply available to the tumor. Consistent with this hypothesis, treatment of mice bearing PC-3 xenografts with a vasodilator increased tumor perfusion and partially restored tumor growth. Moreover, analysis of tumor vascular casts indicated vasoconstriction of tumor-feeding arterioles. Taken together, our data suggest that the local concentration of the ET-1 peptide is critical for determining a balance between its previously unrecognized tumor growth-suppressing activity (vasoconstriction) and known growth-promoting (mitogenesis, survival and angiogenesis) activities. These findings may have implications for the modification of current prostate cancer therapies involving ET-1.
Introduction
ET-1, a peptide originally identified on the basis of its potent vasoconstrictive activity, has been implicated in cancer progression and metastasis. [1] [2] [3] Endothelin peptides, including ET-1 and two isoforms encoded by paralogous genes, ET-2 and ET-3, signal through two G-protein coupled receptors, endothelin receptor A (ETA) and endothelin receptor B (ETB). 4 Receptor activation engages a variety of downstream signaling mechanisms that lead to cell contraction, migration, proliferation and survival. ET-1 expression has been documented in prostate and other cancers, 2, 3 and ET-1, via ETA has been implicated in the osteoblastic response characteristic of prostate cancer bone metastasis. 5, 6 In this context, ET-1 secreted by cancer cells may contribute to a favorable growth microenvironment in bone by acting in a reciprocal paracrine loop with resident osteoblasts. 6 Additionally, it is possible that ET-1 may be involved in autocrine control of cell survival and proliferation and paracrine effects on angiogenesis. 3 The presence of elevated plasma levels of ET-1 in prostate cancer patients combined with the availability of suitable drugs that were originally developed as antihypertensive agents, led to large-scale clinical trials testing the efficacy of endothelin receptor antagonists in advanced prostate cancer. 7 To date, these studies have yielded mixed results with respect to their survival benefit. 8, 9 In order to improve the clinical prospects for endothelin blockade as a treatment for advanced prostate cancer, it is important to clarify the biological mechanism(s) whereby the endothelin axis contributes to prostate cancer progression.
Prior studies have utilized exogenous ET-1 peptide and/or pharmacological inhibitors of endothelin receptors to investigate the role of ET-1 in prostate cancer. Here we have evaluated the consequences of enhanced endogenous ET-1 expression on prostate cancer cells and the tumor microenvironment. To test the role of ET-1 in tumor progression we engineered two well-characterized prostate adenocarcinoma cell lines, 22Rv1 and PC-3, to express elevated levels of ET-1. These cells secreted higher levels of ET-1 peptide into culture medium than did control cell lines; levels comparable to those found in human primary lung microvascular endothelial cells. Consistent with previous findings, increased ET-1 expression promoted cell growth in vitro in an ETA-dependent manner. Surprisingly, though, when we assessed the ability of ET-1-overexpressing prostate cancer cells to grow in a metastatic colonization model or as subcutaneous xenografts, these cells exhibited dramatically reduced tumor growth. Because of the contrasting nature of these initial in vivo observations and the role that ET-1 has in controlling vascular reactivity, we hypothesized that a local vasoconstrictive effect of ET-1 might limit tumor growth by restricting the blood supply. Consistent with this hypothesis, we found that systemic treatment of mice with the vasodilator hydralazine increased growth and perfusion of ET-1 overexpressing tumors, while the microvascular density of ET-1-overexpressing tumors was not consistently affected. Moreover, an evaluation of tumor vascular casts showed that elevated ET-1 expression resulted in the constriction of tumor-feeding arterioles. These studies indicate that ET-1 exerts opposing effects on tumor growth, with the outcome depending on the local expression level of this peptide.
Results
Expression of ETA and ET-1 in prostate cancer cell lines. First, we assessed the levels of both ETA on the cell surface and ET-1 peptide secreted into conditioned medium in prostate cancer (22Rv1, PC-3) and reference cell lines (NIH3T3, PrEC and HMVEC-L) ( Table 1) . Using an ETA-specific radioligand binding assay, we found that the levels of this receptor were five-fold lower in 22Rv1 than PC-3 cells, and that the levels in PC-3 cells were in turn about five-fold lower than in the NIH3T3 line (known to express ETA at high levels). 10 The binding affinities for the ETA-selective antagonist PD151242 were comparable among these cell lines, and ranged from 113 to 163 pM, values similar to those measured in other cell types. 11 Using an ET-1 ELISA, we assessed the levels of ET-1 peptide secreted into the medium by prostate cancer cell lines and those expressing elevated levels of ET-1 from a retroviral vector (22Rv1 ET-1 and PC-3 ET-1) ( Table 1) . We found that 22Rv1 ET-1 cells secreted nearly 80-fold more ET-1 peptide than 22Rv1 vector control cells; similarly, PC-3 ET-1 cells secreted greater than 120-fold more ET-1 peptide than PC-3 vector cells. Notably, the ET-1 peptide in conditioned medium from the vector control cell lines cells achieved a concentration of only 4 pM, which is well below the affinity for ET-1 measured in these cell lines using the radioligand binding assays. We established that the ET-1 secreted from PC-3 ET-1 cells was active by measuring the ability of conditioned media to elicit ETA-dependent contraction of isolated mesenteric veins (data not shown). The levels of ET-1 secreted by 22Rv1 and PC-3 cells were similar to those measured in primary human prostate epithelial cells (PrEC). Although ET-1 expression levels in the engineered cell lines (~300-500 pM) were much higher than in vector control cell lines or PrEC cells, they were similar to the endogenous levels of ET-1 peptide secreted by HMVEC-L cells (~500 pM) and within the range necessary for binding to ETA on these cells.
ET-1 increases autocrine stimulation of prostate cancer cell growth. Exogenously applied ET-1 peptide has been shown to increase the growth of prostate cancer and other cell types in culture via the ETA receptor. 2, [12] [13] [14] As shown above, whereas the endogenous levels of ET-1 produced in the PC-3 and 22Rv1 cell lines are unlikely sufficient to support autocrine growth stimulation in cell culture, forced expression of ET-1 results in the secretion of ET-1 peptide at levels that could potentially support autocrine growth stimulation. To test this, we measured cell growth in both adherent and nonadherent (soft agar) cultures. In adherent cell cultures, elevated ET-1 enhanced the growth of PC-3 cells but not that of 22Rv1 cells ( Fig. 1A and B). In PC-3 cells, ETA inhibition blocked the effect of elevated ET-1, demonstrating that autocrine growth stimulation occurs in this cell line. In soft agar assays ( Fig. 1C-E) , which are often a good indicator of tumorigenic potential, both the 22Rv1 ET-1 and PC-3 ET-1 cell lines demonstrated more than two-fold enhanced growth relative to vector controls ( Fig. 1C and D) . Notably, whereas 22Rv1 ET-1 cells did not exhibit increased growth in adherent cultures, they did when grown in soft agar.
Elevated ET-1 expression in prostate cancer cells abrogates metastatic colonization. The experiments described above are consistent with a role for ET-1 in promoting the growth of prostate cancer cells. To determine the effect of ET-1 overexpression on metastatic colonization, we employed a model previously developed in our laboratory. 15 We injected 22Rv1 ET-1 and 22Rv1 vector cells that express luciferase at comparable levels (data not shown) intracardially, and monitored tumor development over an eight-week period. In contrast to expectations from the results described above, bioluminescence signal in mice injected with 22Rv1 ET-1 cells was significantly reduced compared to that in mice injected with 22Rv1 vector cells ( Fig. 2A) . In 22Rv1 ET-1 injected mice, growth reached a plateau after an initial increase, rising only slightly over a 4 mo period. Although a few tumors with higher signal were evident, these grew very slowly (Fig. 2C) . Importantly, these 22Rv1 ET-1 tumors were distributed in both bone and soft tissue sites suggesting that elevated ET-1 expression does not preferentially affect colonization of specific organ sites. Those ET-1 overexpressing tumors growing in bone exhibited mixed type lytic/blastic lesions (Fig. 2D ) which we have previously reported for the 22Rv1 model. 15, 16 Most mice injected with the vector control cells reached clinical endpoints by 8 w, which is typical for this model. In contrast, the decrease in metastatic colonization in 22Rv1 ET-1 cell-injected mice is correlated with a significant increase in survival (Fig. 2B) . The outcome of this experiment was similar in an independent replicate trial (data not shown).
Since 22Rv1 ET-1 cells exhibited reduced metastatic tumor growth, we hypothesized that metastatic growth might select for lower ET-1 expression. To investigate this possibility, we first analyzed the ET-1 expression levels in 20 clones that we isolated in vitro from the 22Rv1 cell line, as well as in eight cell lines that we derived from in vivo metastatic tumors of 22Rv1 origin. In clones derived in vitro www.landesbioscience.com
Cancer Biology & Therapy 721 Fig. 4C and D) , confirming elevated ET-1 expression in vivo. Although ET-1 has been implicated as a pro-angiogenic factor in other tumor types, we considered the possibility that the poor growth observed in the 22Rv1 ET-1 and PC-3 ET-1 tumors could be due to poor tumor angiogenesis.
To assess this possibility, we stained sections with an anti-CD31 antibody to reveal blood vessels ( Fig. 4C and D). Microvessel density (MVD) was reduced in PC-3 ET-1 subcutaneous tumor samples, whereas it was unchanged in the 22Rv1 ET-1 tumors (Fig. 4E ). To begin to identify mechanisms that might underlie the observed differences in vessel density, we analyzed the concentration of VEGF in the media from vector-and ET-1overexpressing cells. Whereas in 22Rv1 cells, elevated ET-1 increased VEGF expression relative to that in the 22Rv1 controls (49 ± 2 pg/ml/10 5 cells vs. 39 ± 3 pg/ml/10 5 cells, respectively, p < 0.01, t-test), in PC-3 ET-1 cells it resulted in a reduction of VEGF to nearly half that present in the PC-3 vector cells (43 ± 19 pg/ml/10 5 cells vs. 71 ± 8 pg/ml/10 5 cells, respectively, p < 0.05, t-test). Although ET-1-mediated inhibition of VEGF may account for the reduced angiogenesis in PC-3 ET-1 tumors, it does not explain why 22Rv1 ET-1 tumors also failed to grow. Taken together, these results indicate that impaired angiogenesis alone cannot explain the failed tumor growth of prostate cancer cells expressing elevated levels of ET-1.
Growth and perfusion of ET-1 overexpressing tumors is enhanced by systemic treatment with a vasodilator. Because ET-1 functions as a powerful vasoconstrictor, we considered whether elevated ET-1 might act locally on the tumor-feeding blood vessels to reduce blood flow, possibly compromising tumor growth. To test this, we established PC-3 vector and PC-3 ET-1 subcutaneous tumors and treated mice systemically with hydralazine, a vasodilator that acts primarily by relaxing arteriolar smooth muscle. 17 We confirmed that mice treated with this regimen exhibited reduced mean arterial blood pressure and tachycardia, consistent with previous reports documenting from the 22Rv1 parental population, ET-1 expression was heterogeneous, with differences in ET-1 levels relative to those in the parental cell line ranging from 9-420% (compare white bars to the black bar; Fig. 3 ). The mean relative expression level of ET-1 peptide in this collection of clones (0.76 ± 0.11) was similar to that of the parental cell line, indicating that these clones adequately sampled the population. 22Rv1 cell lines isolated from tumors at different organ sites (including liver, adrenal gland and lymph node) following intracardiac injection of the 22Rv1 parental cell line (In vivo passaged 22Rv1 cell lines), the levels of secreted ET-1 were consistently lower than the mean value for the 22Rv1 parental cell population (compare grey bars to the black bar, Fig. 3 ). These findings are consistent with the interpretation that the cells expressing lower levels of ET-1 are selected for growth in this model of metastatic colonization.
Elevated ET-1 does not consistently inhibit tumor angiogenesis. To investigate the mechanisms that retard the growth of 22Rv1 ET-1 hydralazine activity in rodents (data not shown). The subsequent effects of hydralazine on tumor growth were assessed over the duration of the experiment (Fig. 5A) . As had been found in previous experiments ( Fig. 4A and B) , ET-1 tumors were significantly growthinhibited compared to vector control tumors (Fig. 5A) . Hydralazine increased ET-1 tumor growth compared to vehicle only, though it did not fully restore growth to vector control levels. Hydralazine treatment did not significantly affect tumor growth in the vector control. To determine whether the increase in tumor growth in the hydralazinetreated animals was due to a direct effect of hydralazine on tumor cells, we treated PC-3 ET-1 cells with various concentrations of hydralazine in vitro. This did not increase the growth of PC-3 ET-1 cells and, in fact, we observed cytotoxicity at concentrations above 100 μM (data not shown). Prior to euthanizing the mice, we injected Hoechst 33342 intravenously to assess tumor perfusion. (b) increased stability of the ET-1 mRNA due to removal of a portion of the 3'UTR involved in destabilizing the ET-1 transcript. 18 Although these engineered levels of ET-1 are higher than those detected in primary prostate epithelial cells, they were comparable to the endogenous ET-1 production measured in another cell type primary lung microvascular endothelial cells.
A number of studies have found that exogenously supplied ET-1 peptide in the pM to nM range can stimulate the proliferation of a variety of normal and transformed cell types. 2, 12, 14 Based on our initial findings and the studies cited above, we expected that higher levels of ET-1 would enhance prostate tumor growth in vivo. This would also be consistent with the findings from a previous study, in which an 18-fold increase in ET-1 expressed in WISH cells led to enhanced bone formation when these cells were injected adjacent to the mouse tibia (although tumor growth per se was not assessed in this study). 5 We were thus surprised to find that in both 22Rv1 and PC-3 prostate cancer cells, elevated ET-1 expression inhibited tumor growth in vivo, in both metastatic colonization and subcutaneous models. Curiously, the metastatic colonization experiment showed some detectable 22Rv1 ET-1 tumor growth, but this was not robust and explained the corresponding increase in the survival of these animals relative to their control cell-injected counterparts. Importantly, tumor growth was reduced at all metastatic organ sites including bone and soft tissues. This apparent initiation of tumor growth and its sudden restraint led us to consider the possibility that high levels of ET-1 might interfere with tumor angiogenesis. ET-1/ETB signaling has been shown to have direct pro-angiogenic activity on cultured endothelial cells, and to enhance the effect of VEGF. 23, 24 Moreover in normoxic ovarian carcinoma cells, ET-1/ETA signaling has been shown to upregulate VEGF by inducing the VEGF regulatory protein HIF-1α. 25 Finally, ET-1 expression has been found to correlate with VEGF expression and MVD in breast and ovarian carcinomas. 26, 27 Nevertheless the role of ET-1 in angiogenesis and VEGF expression has not yet been investigated in prostate cancer where it might act differently. Our demonstration that elevated ET-1 decreased MVD in the PC-3 xenografts and that this was correlated with reduced VEGF expression by PC-3 cells would not have been predicted based on nuclei (Hoechst-stained blue) are shown (Fig. 5B) . Representative images show that in ET-1 tumors, nuclear Hoechst 33342 staining around CD31 positive hot-spots is reduced compared to that in vector control tumors. Treatment with hydralazine increased dye uptake in both vector and ET-1 tumors. Hydralazine treatment did not affect MVD (Fig. 5C) ; but did increase the perfusion of the Hoechst 33342 dye into ET-1 tumors, toward the levels exhibited in the vector controls (Fig. 5D) .
As a second approach to assessing the role of ET-1-mediated vasoconstriction of tumor-feeding arterioles (vessels with smooth muscle responsive to ET-1), we established vascular casts of both the small ET-1 tumors that had formed and the larger vector control tumors following perfusion of MICROFIL red silicon rubber via the left ventricle. Using this method, only blood vessels in the arterial tree larger than ~20 microns in diameter are labeled. A representative tumor from each group shows the marked difference in the extent of MICROFIL labeling of afferent blood vessels, suggesting that the viscous MICROFIL agent was far less effective at penetrating the ET-1 tumors (Fig. 6A) . To quantitatively evaluate the vascular architecture, we took advantage of the fact that MICROFIL is radio-opaque and performed micro-computed tomographic analysis on these tumors (Fig. 6B ). This analysis revealed that MICROFILlabeled vessels of ET-1 tumors were much shorter and of narrower diameter than in vector controls ( Fig. 6C and D) , indicating that in ET-1 tumors, afferent arterioles are constricted which also suggests lower blood flow to these tumors.
Discussion
Prior studies have implicated ET-1 in cell survival and proliferation and paracrine signaling in the tumor microenvironment, though its precise role(s) in prostate cancer progression remains unclear. Here we sought to probe the role of ET-1 in animal models of prostate cancer metastasis by increasing the expression of ET-1 in prostate cancer cell lines. Using this approach, we achieved levels of ET-1 within the physiologic range necessary for activation of the ETA receptor. The higher levels of ET-1 are likely the combined result of (a) high levels of transcription driven from the CMV promoter and growth of these tumors. Should this be true, elevated levels of ET-1 may after all play an important role in negatively regulating angiogenesis in prostate cancer.
We considered an alternative explanation for the reduced tumor growth in our in vivo models: the vasoconstrictive activity of ET-1 has a deleterious impact on tumor growth. In normal blood vessels, ET-1 released from the endothelium acts on vascular smooth muscle cells causing contraction. Moreover, prior reports showed that ET-1 is an important mediator of myogenic tone in isolated tumor arterioles and that tumor-feeding arterioles may be particularly sensitive to ET-1. 28,29 Thus, it was conceivable that elevated levels of ET-1 these earlier studies and we do not yet understand the basis for these effects. It is possible that in the PC-3 cell line elevated ET-1 expression ultimately leads to the downregulation of ETA and consequently VEGF expression. On the other hand, given that we did not observe any change in MVD in the ET-1-overexpressing 22Rv1 xenografts; failed angiogenesis cannot generally explain the poor growth of both of these ET-1-overexpressing xenografts. One potential caveat to this conclusion should be noted; given that MVD assessments were made on only those ET-1 tumors that were able to grow to a sufficient size for analysis, it is possible that compensatory mechanisms may enable sufficient angiogenesis to support some 30, 31 Although early studies showed increased levels of plasma ET-1 in patients with advanced prostate cancer, it is not clear whether this reflects increased ET-1 expression in prostate cancer cells, increased tumor burden, disruption of barriers that normally compartmentalize ET-1 in the prostatic ducts, extraprostatic sources of ET-1, perhaps associated with therapy, or some combination of these. 2 Presuming that cultured prostatic cells reflect ET-1 expression levels in vivo, our data show no significant difference between two prostate cancer cell lines and primary prostate epithelial cells suggesting that expression of ET1 in prostate cancer cells may not be elevated during disease progression. This finding is in accord with a prior study. 32 The engineered levels of ET-1 expression in this study are considerably higher than those endogenously expressed in PrEC cells or prostate cancer cell lines, however, they serve to illustrate the point that high levels of ET-1 are deleterious to prostate tumor growth, a concept that secreted locally by ET-1 cancer cells might lead to constriction of the adjacent vasculature to perturb blood flow to the tumor site. In support of this we made the following findings: (1) Treatment of mice with the vasodilator hydralazine led to a significant increase in the growth of ET-1 tumors, although it did not completely restore it to the level in the vector control; (2) Hydralazine treatment increased perfusion of ET-1 tumors; and (3) Vascular casts from ET-1 tumors showed constriction of afferent arterioles. Both the stark reduction in the MICROFIL perfusion in ET-1 tumors and the fact that the labeled afferent tumor-feeding arterioles in ET-1 tumors had a shorter persistence length and were narrower than in vector controls are consistent with vasoconstriction in ET-1 tumors. Taken together, these data indicate that growth of ET-1 tumors is inhibited due to poor perfusion, and this is a secondary consequence of the vasoconstriction of tumor-feeding arterioles; thus explaining the disconnect between the in vitro and in vivo consequences of elevated levels of ET-1. Our results raise issues related to the nature of prostate cancer metastasis, and clinical efforts to develop endothelin receptor antagonists as treatment for advanced prostate cancer. Although ET-1 is generally regarded as a factor that promotes tumor growth; the microenvironment might disfavor tumor growth, it is interesting to reconsider the results of clinical trials with ETA antagonists in advanced prostate cancer patients. To date ETA antagonists as single agents have demonstrated mixed results with regard to efficacy in advanced prostate cancer patients. 8, 9 In a recently published Phase II study the ETA-selective antagonist ZD4054, showed no effect on median time to disease progression, but did indicate a survival benefit. 9 Our data raises the interesting hypothesis that this mixed result might be due to the fact that the efficacy of ETA antagonism depends on the level of ET-1 in individual tumor microenvironments. It may block the growth of those tumors expressing lower levels of ET-1 and actually increase growth of tumors expressing higher levels of ET-1-those that might otherwise be dormant due to the vasoconstrictive effects of this peptide. We are currently this study is the first to demonstrate. Moreover, we show that metastatic colonization and tumor growth selects from a heterogeneous population those cells that express lower endogenous levels of ET-1. Perhaps within the nascent tumor, endogenous ET-1 secreted from prostate cancer cells or other cells in the tumor microenvironment locally accumulate to levels that could result in vasoconstriction. This would provide selective pressure for lower ET-1 expression in metastatic tumors.
Taken together with prior studies, our data suggest that ET-1 in the tumor microenvironment has both metastasis-promoting (e.g., autocrine and paracrine growth stimulation) and suppressing ( vasoconstriction) activities, such that productive metastatic colonization depends on balancing these activities. In light of the concept that high local levels of ET-1 expression in the tumor post-fixation. Data represent an average of five replicates (three wells per experiment) ± SEM. Tumor models. All animal experiments were performed in accordance with University of Iowa Animal Care and Use Committee policies. To assess the effects of ET-1 overexpression on metastasis, we employed a model that we have previously described. 15 Tumor dissemination was recorded immediately post-injection and followed weekly using bioluminescence imaging on an IVIS100 (Caliper Life Sciences) as described previously. 15 For subcutaneous tumor models, 22Rv1 or PC-3 cells (1 x 10 6 ) were injected into the periscapular subcutis of male athymic nude mice (eight per group, NCI). Tumor volume was determined by vernier calipers using the formula V = (L x W 2 )/2. When indicated, the vasodilator, hydralazine (1.0 mg/kg/ day, Sigma) was delivered in drinking water for the duration of the experiment. To re-isolate cell lines, tumors were dissected, minced and rinsed in PBS. Following centrifugation (2,000 rpm, 2 min), the tumor fragments were further dissociated in Collagenase 1A (2,000 U/ml) in complete cell medium for 15-30 min at 37°C, with periodic agitation. After a PBS wash and centrifugation, cells were resuspended in complete medium containing 1% penicillin/streptomycin, plus 400 μg/ml G418.
Immunohistochemisty and tumor perfusion analysis. For assessment of ET-1 and CD31 expression in xenografts, 22Rv1 and PC-3 subcutaneous tumors were allowed to grow until control tumors reached a volume of ~1,000 mm 3 . Tumors were excised and fixed (4% paraformaldehyde overnight). The embedded tissues were sectioned (5-7 μM), deparaffinized, and rehydrated. Antigen retrieval was performed by 20 min exposure to proteinase K. Endogenous peroxidases were quenched with 3% hydrogen peroxide for 10 min. Sections were blocked in 10% horse serum followed by ET-1 (R&D systems) or CD31 (BD Pharmingen) primary antibody incubation overnight. Biotinylated secondary antibody was detected using ABC reagent (Vector) and then DAB plus (Dako). MVD was determined by the 'hot spot' methodology (average of three fields/section, two sections/tumor, field = 0.95 mm 2 at 200x, of at least four tumors/ group) to count endothelial cell-lined tumor vessels. 34 Hematoxylin and eosin (H&E) staining was performed using standard procedures. To assess tumor perfusion, Hoechst 33342 (15 mg/kg in100 μl saline, Sigma) was administered intravenously 1 min prior to euthanasia. Tumors and the overlying skin were carefully excised and with a portion of the tumor was fixed in 4% PFA or flash frozen in liquid nitrogen. Frozen sections were cut and fixed in cold acetone and air dried. Sections were then rehydrated and immunostained with CD31 antibody. The vessel staining was determined as above utilizing a fluorescently-tagged secondary antibody (Jackson Labs). Hoechst 33342 signal was imaged under 200x magnification with the UV filter, followed by CD31 fluorescence imaging. The perfused fraction (PF) = area (% of area above threshold)/total vessel density was determined essentially as described previously. 35 MICROFIL casting and micro-computed tomography analysis of tumor vasculature. A subset of animals was selected for resin casting (MICROFIL red, Flow Tech Inc.). In brief, mice were anesthetized (ketamine/xylazine) and perfused with 3 ml MICROFIL, prepared according to manufacturer's instructions, at a rate of 79 ml/h with a syringe pump (Razel Scientific) via the left ventricle. Following perfusion, the resin was allowed to harden for 1 h at 4°C. Tumors and overlying skin tissue were collected and fixed in 4% PFA overnight, cleared and stored in methyl salicylate until imaging was carried out. A Micro-CAT II (Siemens Pre-Clinical, Knoxville, TN) evaluating this hypothesis. If so, this might produce the effect that established, growing metastatic tumors (with lower ET-1) are sensitive to treatment, thus prolonging survival, but dormant metastatic tumor cells (with higher ET-1) are allowed to grow in the face of ETA antagonism resulting in continued disease progression. Since prostate cancer is a heterogeneous disease both among and within individual patients, the outcome of ETA blockade may be difficult to predict and variable. Finally, our study suggests that the vasodilatory properties of ETA antagonists, in addition to being a dose-limiting toxicity, might be counterproductive to anti-tumor efficacy as this effect could help support the growth of tumors that express ET-1 at high levels. Since cells other than prostate cancer cells may contribute ET1 to the tumor microenvironment; the extent of this negative effect is likely to depend on the metastatic organ site involved, inflammation and stromal involvement. Combination strategies aimed at mitigating the vasodilatory effects of endothelin receptor antagonists might thus be one possible avenue for improving the therapeutic outcome in prostate cancer patients.
Materials and Methods
Cell culture and the generation of ET-1 overexpressing cell lines. We obtained 22Rv1, PC-3 and NIH 3T3 cell lines from the American Type Culture Collection and cultured them in the specified media. Primary human lung microvascular endothelial cells (HMVEC-L; Lonza) and prostate epithelial cells (PrEC; Lonza) were grown in EGM-2MV medium (Lonza) and PrEGM medium respectively. Cultures were maintained at 37°C in 95% air and 5% CO 2 , and subcultured as needed. ET-1 overexpressing 22Rv1 and PC-3 cell lines were prepared as follows: An ET-1 cDNA (NM_001955: nucleotides 335 through 973) was amplified by RT-PCR from human aorta mRNA (Ambion) and inserted into the pQCXIP retroviral vector (BD Biosciences). Stable luciferase-expressing 22Rv1 and PC-3 cell lines generated in our laboratory 15 were then subjected to a second round of viral transduction with ET-1-containing and empty vectors, using puromycin selection as described previously. 15 Measurement of ETA, ET-1 and VEGF-A. Measurement of ETA in cell lines was performed by radioligand binding assay as described previously. 33 To measure ET-1 and vascular endothelial growth factor-A (VEGF) in conditioned medium, we utilized an enzyme-linked immunosorbent assay (ELISA). Medium (2 mL) was collected after 48 h exposure to 2.5 x 10 5 cells plated in six-well dishes. ELISAs for human VEGF and ET-1 (R&D systems) were performed as directed. Data are expressed as mean ± SEM from at least three independent measurements.
Cell growth analysis. For measurement of cell proliferation in adherent cultures, cells were plated into 96-well plates at a density of 5,000 cells per well (day 0). Atrasentan (10 nM, ABT-627, Abbott Labs) or vehicle (1:1 DMSO/ddH 2 O) was added in complete medium to the appropriate wells every 2 d (d 1, 3, 5) . Proliferation was assessed every other day (days 1, 3, 5, 7) with (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3 benzene disulfonate (WST-1, Roche Applied Science) as directed. For measurements of cell growth in soft agar, at day 0, 22Rv1 or PC-3 cells expressing ET-1 or the vector control (5,000 cells/well in 0.3% agar in complete medium) were plated onto 0.5% base agar in six-well dishes. Colonies were stained at 14-21 d post-plating, with 0.005% crystal violet and 0.1% citric acid in ddH 2 O. Colony formation was visualized, counted (percent colony formation), and imaged 1-day micro-computed tomography scanner filled with a Kevex micro focus X-ray source (Thermo Electron Corp., Waltham, MA, 0-500 μA; 0-120 kVp; 65 W max power output) was utilized to acquire tumor vasculature images, by methods similar to those previously described. 36 In brief, the radio-opaque MICROFIL resin-filled vessels were scanned in a 43 x 43 mm field-of-view with the isotropic pixel size of 28 μm with a bin setting of two. The tumors were scanned at 80 kVp, 300 μA, 2,000 ms camera exposure with a bin setting of two, collecting 720 projections over 270 degrees (half-scan) as well as 100 bright and dark calibration images. The projections were reconstructed with EXXIM Cobra (Exxim Computing Corp, San Fransisco, CA), using a modified Feldkamp algorithm producing a 28 μm voxel size. Following the reconstruction, 3D vessel analysis was achieved using VIDA 2.0 software. For the purposes of analysis, the tumor image was quartered and one-half of the slices were analyzed at a time. For every sample, 16 vessels were measured and the average persistence length (length of continuous labeling of blood vessels) and diameter were determined for three tumors per group (vector vs. ET-1).
Statistical analysis. Statistical analyses were performed with Prism 4.0 software (GraphPad Software Inc.,). Two-tailed paired t-test, one-way ANOVA followed by a Bonferroni Multiple Comparison Test or Kaplan-Meier methods were used to determine statistical differences where indicated.
